• Akebia Therapeutics’ Senior Vice President and Chief Commercial Officer Nicholas Grund resigned for personal reasons, effective Nov. 6, 2026.
• Grund is set to provide consulting and advisory services to the company from his departure date through April 30, 2027.
• The consulting arrangement allows for early termination with advance written notice.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001517022-26-000071), on October 14, 2026, and is solely responsible for the information contained therein.